The Ophthalmic Drugs Clinical Pipeline 2021​


​Release Date: Q2' 2021
Number of Candidates: 139

Synopsis: As a higher percentage of the global population lives longer, increasing the need for treatment for age related eye disorders such as glaucoma, diabetic retinopathy, cataracts and macular degeneration. In addition, a host of modern lifestyle habits such as poor eating, overworking and the excessive use of visual displays, have created an environment rife with conditions such as dry eye syndrome and myopia.

The ophthalmology space is seeing dozens of novel compounds investigated and is finding innovative ways to deliver them. This multitude of treatment options in development hold the potential for improved therapy options in areas such as glaucoma, dry eye, ocular hypertension, and retinal disease.
The “Ophthalmic Drugs Pipeline 2021” excel sheet presents a look at the major drug candidates currently in the clinical pipeline. The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the ophthalmic drugs market, profiling 146 future candidates.
For a Sample and Inquiries please contact info@snsintel.com

Pricing: The pipeline excel data sheet is available for the following price: 
​
Single User License: USD 1000

Company Wide License (Single Site): USD 1,500

Company Wide License (Global Site): USD 2,500

Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories: 
  • Candidate (Name)
  • Drug Developer(s)
  • Phase
    • Phase I
    • Phase I/II
    • Phase II
    • Phase II/III
    • Phase III
    • Pre-Clinical
    • Pre-Registration
  • Therapeutic Category ​
    • AMD
    • Diabetic Eye Disease 
    • Dry Eye Disease 
    • Glaucoma
    • Retinal Disease
    • Multiple
    • Others
  • Primary Indication(s)
  • Mechanism of Action